Evolus (EOLS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual Meeting scheduled for June 11, 2026, will be held virtually, allowing shareholders to vote and submit questions online.
Shareholders will vote on electing two Class II directors, ratifying the appointment of the independent auditor, and approving executive compensation on an advisory basis.
Proxy materials are distributed electronically to reduce costs and environmental impact, with options for mail delivery upon request.
Voting matters and shareholder proposals
Proposals include: (1) election of Brady Stewart and Vikram Malik as Class II directors until 2029, (2) ratification of Ernst & Young LLP as independent auditor for 2026, and (3) advisory approval of named executive officer compensation.
Board recommends voting FOR all proposals.
Shareholders may submit proposals for the 2027 Annual Meeting by December 30, 2026.
Board of directors and corporate governance
Board consists of six directors divided into three classes, with staggered three-year terms.
Five of six directors are independent; CEO is not independent.
Committees: Audit, Compensation, and Nominating & Corporate Governance, each with written charters and independent members.
Board diversity includes 33% female and 33% ethnically/racially diverse members as of April 2026.
Code of Conduct, insider trading, and clawback policies are in place.
Latest events from Evolus
- Q1 2026 saw 7% revenue growth, positive Adjusted EBITDA, and reaffirmed full-year guidance.EOLS
Q1 202611 May 2026 - Portfolio expansion, market recovery, and loyalty programs drive strong growth outlook.EOLS
Leerink Global Healthcare Conference 20266 May 2026 - Double-digit growth and digital innovation drive sustained profitability and market expansion.EOLS
Investor presentation4 May 2026 - Votes include director elections, auditor ratification, and executive pay approval.EOLS
Proxy filing29 Apr 2026 - Double-digit growth, expanding HA portfolio, and Sculpt approval set the stage for 2026-2028.EOLS
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - Low-cost, quality-driven cannabis operator targets rapid, profitable multi-state growth.EOLS
Investor presentation10 Apr 2026 - 2025 saw double-digit growth and Q4 profitability; 2026 outlook targets margin expansion and sustained growth.EOLS
Q4 20253 Mar 2026 - Record Q2 revenue and first non-GAAP profit drive raised 2024 guidance and global growth targets.EOLS
Q2 20242 Feb 2026 - Achieved early profitability, expanding with new fillers and strong millennial-driven growth.EOLS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase2 Feb 2026